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Setting priorities for stroke care and research
L. B. Morgenstern1* and W. S. Smith2
Recent publications describing the sobering global increase in
stroke mortality and global life years lost due to stroke despite
improvements in developed countries have drawn focus on
the severe impact of stroke in the developing world. At the
same time, three recent interventional trials that failed to
demonstrate an important role for catheter-based therapies in
acute stroke have called into question this expensive use of
technology. Coupling all of this new data leads to the natural
conclusion that a focus on stroke prevention for the develop-
ing world, and for the poor in developed countries, should be
where we set our priorities for the foreseeable future.
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Decisions about where to allocate medical resources are difficult
and merit careful consideration. However, in the field of stroke
these days, the path seems clear. We should be spending our
money on prevention efforts in the developing world and in
reducing domestic stroke disparities in developed countries. A
recent report suggested that although communicable causes of
death were decreasing sharply, noncommunicable causes of death
were making up the difference (1). Stroke, the world’s second
leading cause of death, increased by 26% in the two decades
between 1990 and 2010, and produced a staggering 177% increase
in global years of life lost. Researchers have coined the term, the
‘epidemiologic transition’, to define this remarkable change from
mainly infectious and traumatic causes of death to chronic dis-
eases such as stroke that are now increasingly devastating the
developing world (2). To underscore how important stroke is as a
growing cause of death in Africa, Asia, and other developing
places in the world, one has to consider that for decades, stroke
incidence andmortality have shown substantial declines through-
out the developed world (3). This means that stroke is increasing
so fast in developing countries that it more than makes up for the
reduced mortality seen in the West to continue to rank as the
number two cause of death worldwide.
In the developed world, affluent majority populations show
declines in the stroke burden, whereas the poor and race/ethnic
minorities struggle with continued high stroke rates (4). Efforts to
target the poor and underserved have been few among the most
developed countries. Stroke research has increasingly focused on
high tech means for clot extraction and advanced neuroimaging,
requiring substantial expense, and is only available at relatively
few centers. Just recently, three clinical trials of catheter interven-
tion concluded that these therapies did not produce greater effi-
cacy than Intravenous tissue Plasminogen Activator (IV t-PA) or
nonintervention controls, much less expensive alternatives (5–7).
Such research will continue but most likely at industry’s expense.
While that is ongoing, developed countries’ governmental
resources should be allocated to prevention.We advocate strongly
for prevention efforts for those most in need.
A renewed focus now on stroke prevention is the preferred
approach for three main reasons: (1) we have cost-effective thera-
pies for the main stroke risk factor, hypertension. While a month
supply of a thiazide diuretic costs $4, interventional acute stroke
procedures cost over $10 000 (8) and has not been shown to be
efficacious in randomized controlled trials. (2) There is literally
an epidemic of stroke occurring in the world now. As the global
population ages, this will quickly overwhelm already constrained
health budgets. Acute treatment strategies are not the answer to
this global crisis; prevention is the best and less costly method.
Now is the time to act. (3)We know the risk factors for stroke and
how to conduct effective global interventions.While industry can
tempt clinicians and researchers with money to do device trials,
there is usually little that those most susceptible to stroke, the
poor, can do to encourage researchers and governments to take up
their case. Setting priorities suggests that there is a pot of money,
and that a group of people get to decide how it is spent. That is
obviously not the case here.We need to stand up as physicians and
advocate for scarce governmental resources to better support
stroke prevention for those most at need. Perhaps we are overly
optimistic, but we hope that the collective voice of physicians who
care for stroke patients around the world can make a difference.
We urge readers to make this a priority and act. Specifically, we
hope that readers in developed countries will advocate to their
local and national governments to play stronger roles in stroke
prevention research and treatment, that they will also argue for
similar work towards the elimination of stroke disparities in their
own countries. We hope that those in the developing world will
recognize the growing importance of stroke and work to reduce
this imminently preventable disease. Finally, we hope that every-
one will see their responsibility in their own community, to reach
out to the poor and underserved for cost-effective strategies to
prevent stroke.
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